Table 4.
Univariate and multivariate Cox proportional hazard analysis of LYNX1 expression and disease-specific survival (DSS) for patients with ovarian serous cystadenocarcinoma (OVs) in the validation cohort.
| Characteristics | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Clinical stage (stage I/II vs. stage III/IV) | 2.244 (0.922–5.462) | 0.075 | 2.26 (0.551–9.271) | 0.258 |
| Primary therapy outcome (SD-PD vs. PR-CR) | 0.295 (0.199–0.439) | <0.001 | 0.348 (0.227–0.535) | <0.001 |
| Cancer status (tumor free vs. with tumor) | 15.22 (6.731–34.413) | <0.001 | 19.489 (6.144–61.818) | <0.001 |
| Histologic grade (G1G2 vs. G3G4) | 1.313 (0.833–2.07) | 0.24 | ||
| Tumor residual disease (NRD vs. RD) | 2.559 (1.572–4.166) | <0.001 | 1.141 (0.671–1.938) | 0.626 |
| Anatomic neoplasm subdivision (unilateral vs. bilateral) | 1.034 (0.747–1.431) | 0.841 | ||
| Age (<60 vs. ≥60) | 1.248 (0.944–1.65) | 0.12 | ||
| LYNX1 (low vs. high) | 1.393 (1.053–1.845) | 0.02 | 1.566 (1.13–2.17) | 0.007 |
SD: stable disease; PD: progressive disease; PR: partial remission; CR: complete remission; NRD: no residual disease; RD: residual disease; HR: hazard ratio; CI: confidence interval.